802 results match your criteria: "Mauriziano Hospital[Affiliation]"
J Investig Allergol Clin Immunol
December 2024
ISPA CNR, Torino, Italy.
Clin Genitourin Cancer
November 2024
Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.
Cancer Invest
November 2024
Department of Oncology, University of Turin, Torino, Italy.
Despite a biologically established causative role of viral hepatitis (VH), i.e. HBV and HCV infections, on intrahepatic cholangiocarcinoma (ICC), only few large Western cohorts exploring the association between VH and ICC development are available.
View Article and Find Full Text PDFJ Clin Med
November 2024
Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, 10043 Turin, Italy.
: Nowadays, thanks to the introduction of the VI-RADS scoring system, mpMRI has shown promising results in pre-TURBT assessment of muscular invasiveness of BCa, even if its application in everyday practice is still limited. This might be due to a lack in the literature about the learning curve of radiologists and about the characteristics of the exam. With the aim to reduce scan time and patient discomfort while maintaining diagnostic accuracy, bpMRI has been introduced as a possible alternative to mpMRI in this group of patients.
View Article and Find Full Text PDFOncologist
November 2024
Department of Oncology, Università Politecnica delle Marche, Azienda Ospedaliera Universitaria delle Marche, Ancona 60126, Italy.
Updates Surg
November 2024
Division of Pancreatic Surgery, Department of Internal Medicine and Surgery (DIMEC), IRCCS, Azienda Ospedaliero Universitaria Di Bologna, Alma Mater Studiorum, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti n.9, 40138, Bologna, Italy.
Long-term survivors after pancreatic resection for PDAC are rare, constituting a specific subset of patients that remains poorly understood. The aim of this survey is to describe the current landscape related to survival in the Italian context and identify factors associated with long-term survival. An online survey, conducted by the Italian Society of Oncological Surgery (SICO) and endorsed by Italian Association of the Study of the Pancreas (AISP) and Italian Association of Hepatobiliary Pancreatic Surgery (AICEP), was distributed to surgeons in July 2023.
View Article and Find Full Text PDFJ Allergy Clin Immunol
November 2024
Department of Medicine, DIMED, University of Padova, Padova, Italy; Internal Medicine 1, Ca' Foncello University Hospital, AULSS2, Treviso, Italy.
Background: Respiratory disease is a frequent cause of morbidity and mortality in common variable immunodeficiencies (CVIDs); however, lung function trajectories are poorly understood.
Objective: We sought to determine lung physiology measurements in CVIDs, their temporal trajectory, and their association with clinical and immunologic parameters.
Methods: This retrospective study from 5 Italian centers included patients with CVIDs who had longitudinal pulmonary function tests (PFTs) and chest computed tomography scan available.
BMC Musculoskelet Disord
October 2024
Institute for Biomechanics, BG Unfallklinik Murnau Professor Küntscher Str. 8, 82418, Murnau, Germany.
Introduction: Proximal humerus fractures are usually treated with rigid angle-stable plates or nails. As an alternative, semi-rigid, minimally invasive systems have been developed for supportive fixation. A new system uses this principle with 2.
View Article and Find Full Text PDFESMO Open
November 2024
Department of Oncology, Immuno-Oncology Service, University Hospital of Lausanne (CHUV-UNIL), Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland. Electronic address:
Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of BRCA-mutated (BRCA) and homologous recombination deficiency (HRD)-positive ovarian cancer (OC). While long-term analyses clearly support the use of PARPi as maintenance therapy after first-line chemotherapy, recent data have raised concerns on detrimental overall survival (OS) in non-BRCA OC, a greater incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and unfavorable outcomes following subsequent platinum-based chemotherapy in pretreated OC patients. In this report we discuss the long-term follow-up results from phase III trials in pretreated OC patients, which led to the Food and Drug Administration's withdrawal of PARPi indications in this setting.
View Article and Find Full Text PDFAm J Cardiol
November 2024
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Limited evidence exists concerning the prognostic impact of baseline left ventricular ejection fraction (LVEF) on outcomes among women undergoing transcatheter aortic valve implantation (TAVI), which we aimed to investigate in the present analysis. Patients from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry were categorized according to baseline LVEF into 3 groups: reduced (LVEF ≤40%), mildly reduced (LVEF between 41% and 49%), and preserved (LVEF ≥50%) LVEF. The primary (Valve Academic Research Consortium 2 [VARC-2]) efficacy point was defined as a composite of mortality, stroke, myocardial infarction, hospitalization for valve-related symptoms or heart failure, or valve-related dysfunction at 1 year.
View Article and Find Full Text PDFInt J Mol Sci
October 2024
Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, 10128 Turin, Italy.
The management of advanced endometrial cancer (EC) has changed in the last few years due to the introduction of a new molecular classification and the approval of immunotherapy. For a long time, carboplatin plus paclitaxel was considered the standard treatment for first-line advanced EC, since the approval of the combination of chemotherapy plus immunotherapy. For patients with recurrent EC, with previous platinum-based chemotherapy, single-agent immunotherapy or in combination with tyrosine-kinase inhibitor (TKI) has been approved according to mismatch repair status.
View Article and Find Full Text PDFInt J Biol Markers
December 2024
Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, IRCCS-Fondazione G. Pascale, Napoli, Italy.
Climacteric
November 2024
Coordinator of the Italian Group of Special Interest on Menopause of the Italian Society of Obstetrics and Gynecology, Women's Wellness Foundation, Cagliari, Italy.
Front Immunol
November 2024
Department of Medicine, Azienda Ospedale-Università di Padova, Padova, Italy.
Cancer Immunol Immunother
November 2024
Department of Oncology, University of Torino, Turin, Italy.
Biomedicines
September 2024
Oncology Unit, DAIRI Department, Azienda Ospedaliera Universitaria "SS Antonio e Biagio e C. Arrigo", 15121 Alessandria, Italy.
Int J Mol Sci
October 2024
Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, 10128 Turin, Italy.
Lancet Reg Health Eur
September 2024
National Cancer Institute, IRCCS Fondazione G.Pascale, Naples, Italy.
BMC Cardiovasc Disord
October 2024
Heart Surgery Unit, San Giovanni Battista Hospital - Molinette, Turin, Italy.
J Clin Med
October 2024
Cardiology Department, Mauriziano Hospital, 10128 Torino, Italy.
J Epidemiol Glob Health
December 2024
Department of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Clin Transl Allergy
September 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Eur J Haematol
January 2025
Hematology, Belcolle Hospital, Viterbo, Italy.
J Allergy Clin Immunol Pract
December 2024
MEDCIDS, Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE, Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal.
Background: Treatments for allergic rhinitis include intranasal or oral medications.
Objective: To perform a systematic review with meta-analysis comparing the effectiveness of intranasal corticosteroids or antihistamines versus oral antihistamines or leukotriene receptor antagonists in improving allergic rhinitis symptoms and quality of life.
Methods: We searched four bibliographic databases and three clinical trial datasets for randomized controlled trials (1) assessing patients aged 12 years and older with seasonal or perennial allergic rhinitis, and (2) comparing intranasal corticosteroids or antihistamines versus oral antihistamines or leukotriene receptor antagonists.
Ann Surg
September 2024
Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore.